The role and efficacy of clozapine treatment in early-onset and very early-onset schizophrenia cases: discussion of five cases Schizophrenia is a serious mental disorder emerging at an early age, characterized by significant breakdowns in thought, perception and behavioral processes and withdrawal from human relationships. Psychopharmacologic and psychosocial approaches should be combined for the treatment of schizophrenia. Although the effects and side effects of both typical and atypical antipsychotics have been studied in adult patients in detail, studies in child and adolescent age groups are inadequate. Clozapine is a prototype of atypical antipsychotics and the first antipsychotic to be defined as atypical. Clozapine is often effective in cases in which typical and other atypical antipsychotics fail, and is accepted as the "gold standard" in the treatment of schizophrenia. In this paper, the effects and side effects of clozapine in five adolescent cases diagnosed with schizophrenia are discussed. Four of these cases showed that clozapine is effective in adolescent schizophrenia. While the four cases showing good responses to the treatment tolerated clozapine well, the other case (case 4) showed an apparent decreasing trend in neutrophil count a short while after starting the treatment and his medication was stopped at the request of his parents.
INTRODUCTION
Schizophrenia is a serious mental disorder emerging at an early age, characterized by significant breakdowns in thought, perception and behavioral processes and withdrawal from human relationships 1, 2 . The condition is defined as very early-onset schizophrenia (VEOS) when the symptoms occur before the age of 13 and as earlyonset schizophrenia (EOS) when they set on before the age of 18 3, 4 . In schizophrenia cases emerging in childhood, negative and cognitive symptoms are observed more frequently than positive symptoms. Primary negative symptoms such as failure at school, social isolation, decrease in friend relationships, disorganized behaviors and decrease of interest in daily activities start to develop slowly. Self-care abilities break down. This insidious emergence often delays the diagnosis of the disorder. Psychopharmacologic and psychosocial approaches should be combined for the treatment of schizophrenia. Children and adolescents are more susceptible to side effects than adults 5 . Atypical antipsychotics have been reported to be more effective in alleviating negative and cognitive symptoms compared to typical antipsychotics. Clozapine, a 5-HT2A/D2 receptor antagonist, is a prototype of atypical antipsychotics and the first antipsychotic to be defined as atypical 6 . It has a relatively low affinity for D2 and a high affinity for 5HT2 receptors and therfore its use results in a low occurrence of extrapyramidal side effects. Clozapine binds to 40-50% of D2 receptors in clinically effective doses. Its low effect on D2 receptors and effects on serotonergic (5-HT2, 5-HT1c), adrenergic and cholinergic receptors are related to its characteristic biological profile 7 . Clozapine is unlikely to cause tardive dyskinesia and does not increase prolactin levels. The most serious side effect of the drug is agranulocytosis, which may cause death and is observed in approximately 1% of cases. In addition it may cause intensive sedation, hyper-salivation, seizures, weight gain and myocarditis. Due to its serious side effects, it is not used as the first choice in general, but rather in cases resistant to other treatments 6 . Clozapine is often effective in cases in which typical and other atypical antipsychotics fail, and is accepted as the "gold standard" in the treatment of schizophrenia. Nevertheless, concerns about its side effects limit its use in children and adolescents. In this paper, the effects and side effects of clozapine in five adolescent cases diagnosed with VEOS and EOS are discussed. Side effects were assessed with the Extrapyramidal Symptoms Rating Scale (ESRS); the severity of the disorder was measured with the "Clinical Global Impression Scale/Severity" (CSI-S); improvement rate during the observation process was evaluated with the "Clinical Global Impression Scale/ Improvement" (CSI-I); the level of functionality was appraised with the "Global Assessment Scale" (GAS); and psychotic symptoms were evaluated with the "Scale for the Assessment of Negative/ Positive Symptoms" (SAPS/SANS). General properties of the cases are illustrated in Table 1 .
We believe that our results will be informative for clinicians in cases with treatment-resistant schizophrenia in the pediatric age group.
CASES Case 1
A 15-year-old female, attending the first grade of high school, was admitted to our clinic with complaints of sensitivity, skepticism, fear of getting hurt by people, behaviors injurious to others and herself, hearing directive voices, problems in friend relationships, and isolation. In her history it was pointed out that she had had no problems until 4-5 years previously, but then started to exhibit aggressiveness (e.g. breaking windows) and self-injurious behaviors such as cutting her wrists after a quarrel with a female friend in 6th grade. In the clinic where she was admitted with these complaints, she was diagnosed with "Depressive and Behavioral Disorder" and medicated with sertraline (50 mg/ day) and aripiprazole (5 mg/day); subsequently the dosage was increased to 100 mg/day for sertraline and 10 mg/day for aripiprazole. Although she used the drugs regularly for 8 months, her condition did not improve; the complaints of hearing voices calling her name, commenting on issues, and giving orders such as "kill yourself, argue with your mother" added to her complaints. Her treatment was changed to risperidone (2 mg/day) and aripiprazole (15 mg/ day); a partial improvement was observed as a result of this treatment and her fears diminished. Her previous complaints were reported to have increased in the last year, and she was admitted to our clinic due to two attempts of suicide by cutting her wrists and one by taking drugs. It was discovered that she had had no problems in preperi-postnatal, motor-mental development phases, but had a history of minimal falling over during a play period; otherwise she had not had any trauma/other significant disease/epileptic seizure. She learned how to read and write at the appropriate time, and she was a withdrawn and shy child. In her family background, while her mother and father were not diagnosed with psychopathological disorders, it was stated that substance abuse had been observed in her uncle's son, while her uncle's daughter had attempted suicide and the daughter of her father's aunt had been diagnosed with a "Psychotic Disorder."
In her mental examination, she was observed to have an obese appearance, decreased level of self-care, medium level of cooperation with the doctor, attention deficit, slowed general behavior, depressive mood, and restricted affectivity. She had a low speed of thought, thoughts containing self-injury and suicide, and delusions of persecution and reference. She was observed to have alogia, avolition and auditory hallucinations. Her hemogram, biochemistry and thyroid function tests (TFT), cranial MR and awake EEG results were normal. No substance use history was observed. She was examined by a child endocrinologist for her obesity and was given dietary recommendations. Using the DSM-IV criteria, she was diagnosed with EOS (Paranoid Type). In her initial evaluation, she was classified as "markedly ill" (CGI-S:5). Considering the medication history of the case, she was medicated with risperidone (1.5 mg/day), and the dose was increased gradually up to 3 mg/day over two weeks. No apparent improvement was observed in psychotic findings, and administration of quetiapine treatment was planned. The quetiapine treatment was started with 50 mg/day, and it was increased to 600 mg/day in four weeks; no improvement was observed as a result of the examinations. Treatment with haloperidol was started at 2.5 mg/day, and it was increased to 10 mg/day after two weeks. Since she was observed to have apparent bradykinesia, swallowing difficulty and rigidity, discontinuation of haloperidol and administration of clozapine were decided upon. In the interim evaluation before starting the clozapine treatment, it was observed that there had been no improvement in findings and she experienced apparent extrapyramidal side effects. The clozapine treatment was started with 25 mg/day, and it was gradually increased to 300 mg/day in six weeks. No problem was e n c o u n t e r e d i n h e r w e e k l y h e m o g r a m examinations. An apparent improvement was observed in the positive and negative psychotic symptoms and extrapyramidal findings of the patient during the observation. No side effect was seen except for hyper-salivation, which did not affect functionality. She followed the diet recommendations and no apparent weight gain was observed during the process (75 kg at the beginning and 78 kg in the last examination). In her evaluation after eight weeks, the case was classified as "borderline mentally ill" (CGI:2). The treatment of the case is continuing with 300 mg/ day clozapine.
Case 2
A 17-year-old male, who attended the 11 th grade, was admitted to our clinic with complaints of isolation, reluctance to talk to people, laughing to himself, delusions that people are looking at him and talking about him, and the feeling that his arm muscles are degenerating and changing. In his history, it was stated that his complaints of isolation and reluctance to talk to people had begun one year earlier. He was diagnosed with "Depressive Disorder" in a psychiatry clinic at that time and medicated with sertraline (50 mg/day) and risperidone (1 mg/day). The dose of sertraline was increased to 100 mg/day and the dose of risperidone was increased to 3 mg/day. He used the drugs for approximately 8 months, but no improvement was observed in his complaints; he then discontinued his treatment voluntarily, and after a while his previous complaints increased. He was admitted to our clinic when other complaints such as laughing to himself, oversensitivity, delusions that people are looking at him or talking about him and that his arm muscles are degenerating and changing, thinking that he is being given messages from television and that he is being watched and listened to, hesitation about eating because of the fear that he would be poisoned, and saying that his family is not his real family were added to his previous complaints. No problems were observed during his motor-mental development phases; he did not have epileptic seizures/traumas/other significant diseases; he learned how to read and write at the appropriate time and was a cheerful and likable child having good relationships with his peers. In his family background, it was stated that his father had been monitored for the diagnosis of "Schizoaffective Disorder" for approximately 20 years, his mother had no psychopathological disorder, and his uncle was receiving treatment due to "Psychotic Disorder."
In his mental examination, he showed a decreased level of self-care, medium level of cooperation with the doctor, depressive mood, restricted affectivity, anergia, anhedonia, alogia, avolition and distractibility. He had a low speed of thought, thoughts containing delusions of persecution and reference, somatic delusions and derealization delusions. The severity of negative findings was dominant over positive findings. No visual-auditory hallucinations were observed. His hemogram, biochemistry and TFT, cranial MR and awake EEG results were normal. No substance use history was observed. According to the DSM-IV criteria, he was diagnosed with EOS (Paranoid Type). In his initial evaluation, he was classified as "markedly ill" (CGI-S:5). Considering the fact that he did not respond to risperidone, the administration of olanzapine (10 mg/day) and aripiprazole (2.5 mg/day) was decided upon. The dose of olanzapine was increased to 20 mg/day and the dose of aripiprazole was increased to 15 mg/day gradually and he was evaluated again after eight weeks. Positive and especially negative findings were observed to continue and even increase a little. Administration of clozapine treatment was planned. The clozapine treatment was started at 12.5 mg/day and increased to 25 mg/day after a week. At the end of the second week, the delusions were observed to decline and his communication improved. The dose of clozapine was increased to 75 mg/day by weekly increases of 12.5 mg over six weeks. No problem was encountered in weekly hemogram examinations. In his examination after eight weeks, apparent improvement was observed in the findings and the case was qualified as "borderline mentally ill" (CGI:2). The treatment of the case is continuing with 75 mg/day clozapine.
Case 3
A 13-year-old female, who attended 7 th grade, was admitted to our clinic with complaints of isolation, hesitation about going outside with the fear of being harmed, excessive irritability, aggressiveness, hearing bad words and voices from neighbors, nonsensical laughing and behaviors (nodding, undressing, refusing to dress), and talking nonsensically about marriage and pregnancy. In her history, it was stated that she had had no problems previously. Her complaints had started approximately two months previously, and she was started on risperidone treatment with the primary diagnosis of "Psychotic Disorder". The dose of the drug was increased up to 4 mg/day, and after regular use for approximately one and a half months, she discontinued her treatment voluntarily since no decrease was observed in her complaints. She was admitted to our clinic when her previous complaints increased and excessive irritability and aggressiveness were added to these complaints. It was noted that her motor-mental development phases were normal, she did not have epileptic seizures/traumas/other significant diseases, she had learned how to read and write at the appropriate time and was a withdrawn child having weak relationships with her peers. It was stated that no psychiatric disease history was observed in her parents or her extended family.
In her mental examination, she was observed to have a decreased level of self-care, low level of cooperation with the doctor, dysphoric mood and restricted affectivity. Additionally, disorganized speech, psychomotor agitation, distractibility, auditory hallucinations and impulse control disorder were observed. Her thoughts contained nonsensical repetitions, and her thoughts that she was pregnant and must get married, and delusions of persecution and reference attracted attention. Her hemogram, biochemistry, and thyroid function tests, metabolic screening, cranial MR and awake EEG results were normal. No substance use history was observed. According to DSM-IV c r i t e r i a , s h e w a s d i a g n o s e d w i t h E O S (Hebephrenic Type). In her initial evaluation, she was qualified as "severely ill" (CGI-S:6). Considering the fact that she did not respond to risperidone, her treatment was changed to 15 mg/ day olanzapine. As a result of our observations, the dose of olanzapine was increased up to 30 mg/day, and since no improvement was observed in her complaints after four weeks, haloperidol treatment was started at 5 mg/day. The dose of haloperidol was increased to 15 mg/day under controlled conditions, but her symptoms were observed to continue in her examination after four weeks. The administration of clozapine was decided upon. The clozapine treatment was started with 25 mg/day and increased to 300 mg/ day in three weeks. No problem was observed in her weekly hemogram controls. When the dose was increased to 300 mg/day, she was observed to have tachycardia (heart rate: 115/min), which responded to 80 mg/day propranolol. An apparent improvement in her complaints was observed in an evaluation after 8 weeks, and she was qualified as "mildly ill" (CGI-S:3). The clozapine treatment of the case is continuing with the dose of 300 mg/ day.
Case 4
A 13-year-old male, who attended 8th grade, was admitted to our clinic with complaints of sensitivity, thinking that he would get hurt by his friend named "A". He reported that A watches and follows him all the time, his teachers are giving him wrong information deliberately, and he is given messages by television, which started one year earlier. In his history it was stated that he was admitted to a child psychiatry center due to attention problems at the age of 11. He had used long-acting, extended release methylphenidate for 1.5 -2 years, and when the previously described complaints were added in the last year, he was diagnosed with "Atypical Psychotic Disorder" in the same center six months ago and medicated with risperidone and trifluoperazine. He was using risperidone (2 mg/day) and trifluoperazine (4 mg/ day) when admitted to our clinic. In his interview, he stated that he was constantly followed by his friend "A" and that A was responsible for every bad event he experienced, his teachers were giving wrong information deliberately to make him fail, and he received some messages while watching television. In his background, it was stated that no problems had been observed during the pre-peripostnatal periods and motor-mental development phases, and he did not have epileptic seizures/ traumas/other significant diseases in his infancy or childhood. It was found out that he learned how to read and write at the appropriate time, he had problems in his lessons in sixth grade due to his attention deficit, and he was started on methylphenidate, and his expressions in the 7th grade include "I am lonely, nobody wants to play with me, my teachers teach me wrong things." In his family background, it was stated that while the nuclear family had no psychopathological history, his cousin (daughter of his aunt) was using risperidone and aripiprazole with the diagnosis of "Schizo-Obsessive Disorder," and the daughter of his mother's uncle was diagnosed with "Schizophrenia."
In his mental examination, he was observed to have clothing appropriate for his age, decreased level of self-care, normal level of cooperation with the doctor, dysphoric mood, and restricted affectivity. Additionally, a moderate level of irritability, avolition, problems in relationships with his peers, low level of academic success and auditory hallucinations were observed. His thinking process was observed to be normal, and delusions of persecution and reference were conspicuous. His hemogram, biochemistry and thyroid function tests, cranial MR and awake EEG results were normal. No substance use was observed. Using DSM-IV diagnosis criteria, he was diagnosed with VEOS (Paranoid Type). In his initial examination, he was qualified as "severely ill" (CGI-S:6). He was observed with hypersalivation, and since this condition was considered to be related to trifluoperazine, the treatment was ended. He was started on risperidone 3 mg/day, however the active psychotic findings were observed to continue in his examination three weeks later. He was observed to have apparent gynecomastia, and his prolactin level was measured to be 35.85 mcg/dl. As no apparent improvement was observed after the risperidone treatment, administration of aripiprazole treatment was planned. He was started on aripiprazole at 2.5 mg/day, and the dose of the drug was gradually increased to 30 mg/day. A partial improvement was observed with this treatment; however, since the auditory directive hallucinations continued, treatment options such as amisulpride (discontinued due to prolactin increase and gynecomastia), quetiapine (discontinued as it was ineffective), and haloperidol (discontinued as it increased irritability) were used. Finally, olanzapine was added to his treatment. While a partial improvement was observed in his psychotic findings during the administration of aripiprazole (20 mg/day) and olanzapine (20 mg/day), his delusions of reference continued. In his interim evaluation, he was classified as "moderately ill" (CGI-S:4). The administration of clozapine was decided upon as the last resort. Blood examinations were carried out (initial leukocyte count: 7100/mm 3 , neutrophil count: 3000/mm 3 ). The treatment was started with 6.25 mg/day and the dose was increased to 18.75 mg/day in 3 weeks. A decreasing trend was observed in his leukocyte and neutrophil counts in his weekly hemograms. His leukocyte count was detected as 5160/mm 3 and his neutrophil count was detected as 1760/mm 3 in his hemogram three weeks later.
The decreasing trend of the neutrophil counts and the increasing complaints of the patient (interpreted as drug resistance), made his parents worried. They did not want to continue this treatment, and clozapine treatment was discontinued because of the parental disapproval. His neutrophil count was observed to increase to 2260/mm 3 in his hemogram after one week. The treatment of the case was continued with aripiprazole (20 mg/day) and olanzapine (20 mg/ day).
Case 5
A 17-year-old female, who attended 12 th grade, was admitted to our clinic with complaints of sexual expressions such as "I am lesbian, I look at women's genitalia and masturbate," hearing voices, grabbing a knife and showing aggressive behavior in order to silence the voices, sleeping disorder, desire to sit in a dark room, and fear of getting hurt by others. In her history, it was stated that she had been admitted to a psychiatry polyclinic approximately nine months ago with complaints of not sleeping for three consecutive days, locking herself in a dark room, talking to herself aloud and hearing bad words; at that time she was started on risperidone 3 mg/day and was given inpatient treatment for 44 days with the primary diagnosis of "Psychotic Disorder". Upon an increase in her psychotic findings and a decrease in her self-care during her inpatient treatment, the dose of risperidone was increased to 4 mg/day; since no response was observed, she was started on amisulpride at 400 mg/day, citalopram at 10 mg/day and lorazepam at 5 mg/ day. The symptoms showed regression and she was discharged in partial remission. Upon the occurrence of complaints of galactorrhea, weight gain and hair loss in her examinations after discharge, the treatment of amisulpride was reduced by decreasing the dose. She was started on aripiprazole 5 mg/day, and consequently she was admitted to our clinic upon an increase in her psychotic complaints. In her background, it was stated that she exhibited a minimal delay in her motor development, she resembled her peers with regard to language and speaking, and she had mentioned some apparitions in the room after she had a high fever at the age of 3. She had no history of accident, trauma or epileptic seizure during her development stage, and was stated to have a medium level of success during elementary, secondary and high school periods. In her family background, it was stated that the parents had no known psychopathological disorder, but the two grandchildren of the father's aunt were given inpatient treatment for a while in a psychiatric hospital due to psychiatric disorders, but no detailed information was received regarding their disorders.
In her mental examination, she was observed as overweight, having decreased self-care, an inclination towards cooperation with the doctor, decreased attention, dysphoric mood and restricted affectivity. She was observed to have delusions of persecution and reference, slow speed of thought, breakdown in her perceptions and auditory and visual hallucinations. Having a mild level of anhedonia, she was observed to have apparent avolition and insomnia. Her hemogram, biochemistry and thyroid function tests, cranial MR and awake EEG results were normal. No substance use history was observed. Using DSM-IV criteria, she was diagnosed with EOS (Paranoid Type) and admitted to our service. In her initial evaluation, she was classified as "severely ill" (CGI-S:6). She was started on aripiprazole at 10 mg/day and quetiapine at 50 mg/day. The dose of quetiapine was gradually increased to 700 mg/day in two weeks during the observation. No regression was observed in her symptoms. Haloperidol was added to her treatment at a dose 5 mg/day. Since no improvement was observed in the findings of the patient, she was treated with haloperidol (2.5 mg) and biperiden (2.5 mg) injected intramuscularly. The dose of haloperidol was increased up to 20 mg/day in four weeks under controlled conditions. No improvement was observed in the symptoms after one month. The administration of clozapine treatment was decided upon. She was started on clozapine 12.5 mg/day and the dose was gradually increased up to 175 mg/day in four weeks. No problem was encountered in her weekly hemogram examinations. Apparent improvement was observed in positive and negative psychotic symptoms. No extrapyramidal side effects were seen. Her delusions of persecution and reference showed a decrease, auditory hallucinations continued at a mild level and the case showed a tendency to gain insight. At this stage, the case was classified as "mildly ill" (CGI-S:3). The case was discharged in this condition and her clozapine treatment is continuing at 175 mg/day.
DISCUSSION
This paper evaluates the efficacy and side effect profile of clozapine treatment in five adolescent cases, one with VEOS diagnosis and four cases with EOS diagnosis. The clinical examination results of four cases (Case 1-2-3-5) showed that clozapine is effective on adolescent schizophrenia. While the four cases showing quite a good response to the treatment tolerated clozapine well, the other case (Case 4) showed an apparent decreasing trend in neutrophil count a short while after starting the treatment and his medication was stopped at the request of his parents. One case (Case 1) was observed with hyper-salivation, which did not affect functionality, and mild weight gain, and another case (Case 3) was observed with a mild tachycardia responding to propranolol treatment; however, the severity of these complaints did not require stopping the treatment, and no other side effects were encountered.
Since our cases had psychotic symptoms resistant to typical/atypical antipsychotic treatment they had been given previously, and the second case especially had dominant negative symptoms, administration of clozapine treatment was decided upon as a last resort, and apparent clinical improvement and increase in functionality were observed in all cases but one, whose treatment was stopped due to neutropenia. This situation appears to agree with the studies in the literature highlighting the efficacy of clozapine in resistant schizophrenia cases. Kumra et al. compared clozapine and haloperidol treatment in VEOS and EOS cases with 270 children and adolescents and found that clozapine is more effective than haloperidol 8 . Masi et al. stated that four children around the ages 10-12 who did not respond to typical antipsychotics responded well to clozapine at doses of 175-300 mg/day, and improvements in both their negative and positive symptoms were observed around the 2 nd and 3 rd weeks 9 . In our second case, negative symptoms were dominant over positive symptoms. Considering the family background of this case, the patient, who had not responded to two typical antipsychotics and showed resistance, was started on clozapine, and the dose was increased gradually and under controlled conditions. A high degree of improvement was observed in the findings of the case in the examination. There are some studies in the literature stating that clozapine is effective on negative symptoms. Kumra et al. 10 stated that both clozapine and high dose olanzapine reduced the severity of the disorder in child and adolescent schizophrenia patients who were resistant to treatment with at least two atypical antipsychotic groups, and that clozapine and olazapine were effective in the improvement of all clinical parameters. In addition, they stated that clozapine is superior to olanzapine in diminishing the negative symptoms 10 . Clozapine is a prototype of atypical antipsychotics 6 . Due to the risk it poses of serious side effects such as granulocytopenia, agranulocytosis 14 and epileptic seizures, it is used for patients who do not respond to other antipsychotics. A study showed that the risk of neutropenia in children and adolescents treated with clozapine (16%) was higher than in the adult population (3%) 11 . In the literature, there are also some studies showing that early age and male gender are risk factors for neutropenia 12 . Our case 4 was showed a decreasing trend in the neutrophil count with the start of the clozapine treatment. Clozapine treatment was stopped due to the concerns of the patient's parents. We do not know how the therapeutic process and leukocyte count of the patient would have continued if clozapine treatment had not been stopped.
In conclusion, it is proposed that clozapine may be an effective option in child and adolescent schizophrenia cases with no risk factors. The findings need to be supported with double-blind, randomized and placebo-controlled studies with a larger number of cases.
